Contrast agents
    1.
    发明授权
    Contrast agents 失效
    对比剂

    公开(公告)号:US5529766A

    公开(公告)日:1996-06-25

    申请号:US119218

    申请日:1993-10-29

    摘要: The invention relates to ultrasound contrast agents comprising vesicles comprising a protein capable of formation of gas-containing vesicles, wherein the vesicles contain gas which comprises sulphur hexafluoride or a low molecular weight fluorinated hydrocarbon. These contrast agents exhibit stability in vivo upon administration so as to permit ultrasound visualization while allowing rapid subsequent elimination from the system.

    摘要翻译: PCT No.PCT / EP92 / 00716 Sec。 371日期:1993年10月29日 102(e)日期1993年10月29日PCT 1991年3月28日PCT公布。 出版物WO92 / 本发明涉及包含囊泡的超声波造影剂,其包含能够形成含气囊泡的蛋白质,其中囊泡含有包含六氟化硫或低分子量氟化烃的气体。 这些造影剂在施用时在体内表现出稳定性,以便允许超声可视化,同时允许从系统快速随后的消除。

    Gaseous microparticles as ultrasound contrast agents
    3.
    发明授权
    Gaseous microparticles as ultrasound contrast agents 失效
    气体微粒作为超声造影剂

    公开(公告)号:US5569449A

    公开(公告)日:1996-10-29

    申请号:US462401

    申请日:1995-06-05

    CPC分类号: A61K49/223

    摘要: This invention relates to ultrasound contrast agents in the form of microparticles comprising a biotolerable matrix (e.g. of a carbohydrate or an X-ray contrast agent) in association with a gas or a precursor therefor. The contrast agents are stabilized to enhance their in vivo stability and/or echogenicity by covalently modifying the structure of the matrix, e.g. to introduce crosslinking groups or to attach lipophilic groups and/or molecules. The covalent moieties may include biodegradable linkages to assist rapid subsequent elimination of the contrast agents from the system.

    摘要翻译: 本发明涉及包含与气体或其前体相关联的生物可耐受基质(例如碳水化合物或X射线造影剂)的微粒形式的超声造影剂。 通过共价修饰基质的结构,使造影剂稳定以增强其体内稳定性和/或回声性。 引入交联基团或附着亲脂基团和/或分子。 共价部分可以包括可生物降解的键,以帮助快速随后从系统中消除造影剂。

    Contrast agents
    4.
    发明授权
    Contrast agents 失效
    对比剂

    公开(公告)号:US5558857A

    公开(公告)日:1996-09-24

    申请号:US146115

    申请日:1993-12-23

    CPC分类号: A61K49/223

    摘要: This invention relates to ultrasound contrast agents in the form of microparticles comprising a biotolerable matrix (e.g. of a carbohydrate or an X-ray contrast agent) in association with a gas or a precursor therefor. The contrast agents are stabilized to enhance their in vivo stability and/or echogenicity by covalently modifying the structure of the matrix, e.g. to introduce crosslinking groups or to attach lipophilic groups and/or molecules. The covalent moieties may include biodegradable linkages to assist rapid subsequent elimination of the contrast agents from the system.

    摘要翻译: PCT No.PCT / EP92 / 01327 Sec。 371日期:1993年12月23日 102(e)日期1993年12月23日PCT提交1992年6月3日PCT公布。 出版物WO92 / 21382 日期1992年12月10日本发明涉及包含与气体或其前体相关联的生物可耐受基质(例如碳水化合物或X射线造影剂)的微粒形式的超声造影剂。 通过共价修饰基质的结构,使造影剂稳定以增强其体内稳定性和/或回声性。 引入交联基团或附着亲脂基团和/或分子。 共价部分可以包括可生物降解的键,以帮助快速随后从系统中消除造影剂。

    Iodinated esters contrast medium and use
    5.
    发明授权
    Iodinated esters contrast medium and use 失效
    碘化酯造影剂和使用

    公开(公告)号:US5370861A

    公开(公告)日:1994-12-06

    申请号:US210739

    申请日:1994-03-21

    摘要: Water insoluble iodinated esters of formula (I), in which R.sup.1 is a substituted or unsubstituted C.sub.1-20 aliphatic, C.sub.7-20 araliphatic or C.sub.6-20 aryl group or a C.sub.1-20 heterocyclic group having one or more hetero atoms selected from O, S and N; R.sup.2 is hydrogen or a substituted or unsubstituted C.sub.1-6 aliphatic, C.sub.6-10 aryl or C.sub.7-20 araliphatic group; and R.sup.3 is a group as defined above for R.sup.1, which may be the same as or different from R.sup.1, or R.sup.2 and R.sup.3 together represent a substituted or unsubstituted C.sub.1-4 alkylene group, the molecule containing at least one iodine atom and being metabolisable to products which are soluble in body fluids and are physiologically acceptable. The esters are useful in X-ray and ultrasound imaging, especially liver and spleen imaging.

    摘要翻译: PCT No.PCT / EP90 / 00053 Sec。 371日期1991年5月20日 102(e)日期1991年5月20日PCT提交1990年1月8日PCT公布。 出版物WO90 / 07491 日本1990年7月12日。式(I)的水不溶性碘化酯,其中R 1是取代或未取代的C 1-20脂族,C 7-20芳烷基或C 6-20芳基或具有一个或多个 更多的选自O,S和N的杂原子; R2是氢或取代或未取代的C1-6脂族,C6-10芳基或C7-20芳脂肪基; 并且R 3是如上对R 1所定义的基团,其可以与R 1相同或不同,或者R 2和R 3一起表示取代或未取代的C 1-4亚烷基,该分子含有至少一个碘原子并且可代谢至 可溶于体液且具有生理学上可接受的产品。 这些酯可用于X射线和超声成像,特别是肝脏和脾脏成像。

    Contrast agents
    9.
    发明申请
    Contrast agents 审中-公开
    对比剂

    公开(公告)号:US20070003485A1

    公开(公告)日:2007-01-04

    申请号:US11448601

    申请日:2006-06-06

    IPC分类号: A61K49/00

    摘要: The invention relates to ultrasound contrast agents comprising vesicles comprising a protein capable of formation of gas-containing vesicles, wherein the vesicles contain gas which comprises sulphur hexafluoride or a low molecular weight fluorinated hydrocarbon. These contrast agents exhibit stability in vivo upon administration so as to permit ultrasound visualization while allowing rapid subsequent elimination from the system.

    摘要翻译: 本发明涉及包含囊泡的超声波造影剂,其包含能形成含气囊泡的蛋白质,其中囊泡含有包含六氟化硫或低分子量氟化烃的气体。 这些造影剂在施用时在体内表现出稳定性,以便允许超声可视化,同时允许从系统快速随后的消除。

    Contrast agents
    10.
    发明申请
    Contrast agents 审中-公开
    对比剂

    公开(公告)号:US20050232865A1

    公开(公告)日:2005-10-20

    申请号:US11055543

    申请日:2005-02-10

    摘要: The invention relates to ultrasound contrast agents comprising vesicles comprising a protein capable of formation of gas-containing vesicles, wherein the vesicles contain gas which comprises sulphur hexafluoride or a low molecular weight fluorinated hydrocarbon. These contrast agents exhibit stability in vivo upon administration so as to permit ultrasound visualization while allowing rapid subsequent elimination from the system.

    摘要翻译: 本发明涉及包含囊泡的超声波造影剂,其包含能形成含气囊泡的蛋白质,其中囊泡含有包含六氟化硫或低分子量氟化烃的气体。 这些造影剂在施用时在体内表现出稳定性,以便允许超声可视化,同时允许从系统快速随后的消除。